pharma · Systemic Sclerosis · Nonalcoholic Steatohepatitis · CMMB
Chemomab Therapeutics
Chemomab Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Tel Aviv, USA
- Founded
- 2011
- Employees
- 20
- Programs
- 6
- Drugs
- 4
- Patents
- 4
Chemomab Therapeutics projects
6 ClinicalTrials.gov programs sponsored by Chemomab Therapeutics.
Chemomab Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
10 mg/kg CM-101
Chemomab Therapeutics
Systemic Sclerosis
1 trial -
5 mg/kg CM-101
Chemomab Therapeutics
Nonalcoholic Steatohepatitis
1 trial -
Anti-human CCL24 monoclonal antibody (CM-101)
Chemomab Therapeutics
Primary Sclerosing Cholangitis
1 trial -
Anti-human CCL24 monoclonal antibody (CM-101)
Chemomab Therapeutics
Healthy
1 trial -
Anti-human CCL24 monoclonal antibody (CM-101) - Part One
Chemomab Therapeutics
Nonalcoholic Fatty Liver Disease
1 trial -
CM-101
Chemomab Therapeutics
Nonalcoholic Steatohepatitis (NASH)
1 trial
Frequently asked questions
How many clinical projects does Chemomab Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.